Amicus Therapeutics (FOLD) Misses Q3 EPS by 56c, Revenues Miss; Offers FY18 Revenue Outlook Below Consensus

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/24/2026

1. RNG
2. DECK
3. WDC
4. BYD
5. SPOT
6. WCN
7. BMY
8. TSCO
9. BE
10. SPY

Go back to Amicus Therapeutics (FOLD) Misses Q3 EPS by 56c, Revenues Miss; Offers FY18 Revenue Outlook Below Consensus

Amicus Therapeutics Announces Third Quarter 2018 Financial Results and Corporate Updates

November 5, 2018 7:00 AM EST

U.S. Galafold® (Migalastat) Fabry Launch Tracking Significantly Ahead of Expectations- 100+ Patients Prescribed Galafold Since August Launch

3Q18 Global Galafold Net Product Sales of $20.6M Driven by Continued International Growth - 500+ International Fabry Patients Now on Galafold

Reaffirming Higher End of FY18 Revenue Guidance of $80M-$90M Balance Sheet Strength Sufficient to Fund Operations into at least 2021

Gene Therapy Pipeline Provides 14 New Programs and... More